Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? - Wikidata - wikimedia - TriplyDB

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

http://www.wikidata.org/entity/Q36763425

about

Epidemiology and clinical course of Crohn's disease: results from observational studies Light and sound - emerging imaging techniques for inflammatory bowel disease.Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?Diet therapy for inflammatory bowel diseases: The established and the new Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Review article: diet and inflammatory bowel disease--epidemiology and treatment.Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.Limitations in assessment of mucosal healing in inflammatory bowel disease Dietary phenethylisothiocyanate attenuates bowel inflammation in mice.Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study.Clinical and Pathologic Remission of Pediatric Ulcerative Colitis with Serum-Derived Bovine Immunoglobulin Added to the Standard Treatment Regimen Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy.Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study.Gene expression analysis of peripheral cells for subclassification of pediatric inflammatory bowel disease in remission.Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation.Histological healing after infliximab induction therapy in children with ulcerative colitis Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance.Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease.What predicts mucosal inflammation in Crohn's disease patients?Recent advances in the medical therapy of Crohn's disease in childhood.Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach Transition of Care in Inflammatory Bowel Disease.Nilotinib-mediated mucosal healing in a rat model of colitis.Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.Are we giving biologics too much time? When should we stop treatment?Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.What is the optimal therapy for Crohn's disease: step-up or top-down?NOD2 status and human ileal gene expression.Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

P2860

Q22241217-EF39E493-94F8-4274-AB22-F5CE6A235DD6 Q26739059-CDFD0AD7-983C-4392-AD0F-77300AFFFEDB Q26765352-F5E2B9C1-7179-478F-8374-8B6A1C65CAA7 Q26768564-E380839E-8B1C-4083-B43F-5507A0E878C1 Q26829488-6E1DFFD9-A786-4D9D-9173-238DC8435ACD Q33445163-35E74863-0A36-45AD-B065-5FBC32468D47 Q33562796-E0999EED-24F0-41BD-9F9B-427B69E9FFD7 Q33564132-126C5B38-C157-4635-AD68-0A97D21B1BB9 Q33564957-8F47A7BF-BF35-48B8-85CA-8CBC15B214E7 Q33566354-AA166700-FD6A-44A5-BD83-0305E7547E5E Q33646476-91514729-BD0C-42E6-AC0F-073B5237FB76 Q33694759-F221CAE7-BD8A-45B1-BD1D-FFEDE5D67A6E Q33801631-26A5637C-B361-4956-B8DB-43366483FDEF Q33810986-3F63C3E2-9D64-4E8C-91F8-492E68EA25C3 Q33819484-CB5B7A3F-9672-4D7F-8C27-C5F6CB9B45B4 Q34342534-839609FE-1A51-4B16-883F-F12352F387DC Q34374449-0CC059BD-F761-4686-92F9-5AE2739B686D Q34637725-C336F4CE-EB1A-4053-A403-368EDE39BCAA Q34993630-644ADE33-F194-43DB-8E36-21598607A565 Q35008312-AB4B5923-7471-49F5-BCEE-0CA1A5F216D2 Q35048529-15B4E44E-7FED-4B68-80D4-13512F03B344 Q35621160-5EB563ED-FA92-49FE-A3B5-A1319076085B Q36105637-9FD6F3ED-6ED6-4D52-89A9-1187DE20CDBE Q36116908-21E40EBE-289F-465C-A06E-AFE19768F984 Q36167373-59C1ED2D-FDFC-43AA-B407-DE865D18C9F4 Q36550808-D2ADFDE7-7A0C-4E7F-9C33-FBC856507E79 Q36578893-50CA5BC5-E78A-4A30-AF13-40AA942BE17C Q36655221-5AC35B0C-1D12-4BFD-B5D1-DB23C3DFFAE3 Q36896566-48422A40-B184-47BF-8BC5-28CA615D140A Q36968175-D816AE05-14C0-4F04-9AE3-F589DEFEF6E1 Q37156633-8F58044B-41E7-4D19-9E7F-8C282D44B294 Q37182818-237E28CF-9CAD-4678-AF8C-0441D1525788 Q37208138-46D4F113-266D-478F-8A43-271BDC304663 Q37273489-478E776C-0AC0-4DEE-86E6-E170FDD95B7E Q37276975-0400AF17-AC9C-464A-ACE8-B05993D7729F Q37304268-7E74B00A-6068-4603-9EEC-F8E4912B7CB6 Q37442760-DF83BDB8-89F9-4F40-8531-F9BB6DE3C86B Q37720746-F8BC16AA-4C62-48D7-8DEB-D5ABC147B53F Q37727940-7E5B90A0-09B3-454D-9F0D-C675130C921B Q37814566-18BE228A-C9BF-42D4-907E-B38DF99F1651

P2860

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

http://www.wikidata.org/entity/Q36763425

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@ast

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@en

type

label

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@ast

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@en

prefLabel

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@ast

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@en

P1433

Q36763425-6550DCEF-1C80-4950-B3CC-945E77D635B1

P1476

Q36763425-1AC9EE28-8B97-4B1E-ACBD-BFC70906D8DF

P2093

Q36763425-EFB16DD9-E8AE-4150-863D-91BD88A0A369

P2860

Q36763425-00E95D0F-8F5B-45C9-BF49-A4A50193C0EA

Q36763425-3759470A-8316-481E-98CF-27AAD2DD454C

Q36763425-54529BEF-C3AC-428B-8C84-E4BC6C074E37

Q36763425-74B7B489-5AA6-4F92-B810-8F699F9B5690

Q36763425-782D8111-C954-469E-839D-8F0C9BFF8AC3

Q36763425-80490B3D-4260-40BB-A4E1-F8FE0356141D

Q36763425-A78BEC95-F658-44BC-A25C-8792ABCDAE6B

Q36763425-AF0821E8-B187-4ADA-853C-23DC17751D10

Q36763425-B7608A3D-2246-4F7D-977E-C567EE16C7A3

Q36763425-F14F68C6-3478-4166-B17C-B35914534A7F

P304

Q36763425-081F39D1-57E2-482A-8B92-33635924D047

P31

Q36763425-DBC7B1BA-4749-45D3-8886-D510F23B5889

P356

Q36763425-BE90C840-2030-47A2-B719-9B0355B6B9B3

P407

Q36763425-ADF95725-D9E5-40BF-AC01-B0DAB85E1F29

P433

Q36763425-0852C36E-7BCB-4967-81CC-4FE20EA6EFC2

P478

Q36763425-529A9592-E7AD-45CF-B48F-382D235E1A75

P50

Q36763425-CC01C1FC-3A7A-4D96-A4CC-08172A40436B

Q36763425-DDCE8892-1644-4FBB-A33B-523D9DB64234

P577

Q36763425-8F7D6D64-8F28-453D-9637-9297DE908B2B

P5875

Q36763425-4DF285E2-5987-416E-A011-DB2983B4F175

P698

Q36763425-DFC24C66-0CFD-4CF0-8BB5-D77C6DCE4978

P921

Q36763425-86464FDE-2E8C-4254-9C66-D14D92E95D50

Q36763425-A64295B8-82F1-4DB8-8DA4-65FE6D2127ED

P932

Q36763425-3D757572-CB0D-4AC2-890B-138C3AEEE355

P356

GUT.2005.088732

P1433

P1476

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

@en

P2093

Severine Vermeire

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.

A controlled double blind study of azathioprine in the management of Crohn's disease

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

Long-term evolution of disease behavior of Crohn's disease.

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

P304

453-455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2005.088732

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Gert Van Assche

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6438823

http://www.w3.org/2001/XMLSchema#string

P698

17369375

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

1856849

http://www.w3.org/2001/XMLSchema#string